July 26, 2019 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from April 26, 2019 (vote required)
2. Approval of minutes from April 26, 2019 (vote required)
»
3. Re-drawing of member terms to establish term length: Stephanie Gutierrez – Advisory Committee Coordination Office
3. Re-drawing of member terms to establish term length: Stephanie Gutierrez – Advisory Committee Coordination Office
»
4. New business: » - a. Alzheimer’s agents b. Antihistamines, minimally sedating c. Antihypertensives, sympatholytics d. Calcium channel blockers e. Cephalosporins and related antibiotics f. Fluoroquinolones, oral g. Glucocorticoids, oral h. Immunosuppressives, oral i. Iron, oral j. Leukotriene modifiers k. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) l. Ophthalmic antibiotics m. Ophthalmic antibiotic-steroid combinations n. Ophthalmic for allergic conjunctivitis o. Ophthalmic, anti-inflammatories p. Ophthalmic, anti-inflammatories/immunomodulator q. Ophthalmic, glaucoma agents r. Otic antibiotics s. Otic anti-infectives and anesthetics t. Progestational agents u. Sickle cell anemia treatments v. Skeletal muscle relaxants w. Steroids, topical high x. Steroids, topical low y. Steroids, topical medium z. Steroids, topical very high aa. Ulcerative colitis agents
4. New business: »
a. Alzheimer’s agents b. Antihistamines, minimally sedating
c. Antihypertensives, sympatholytics
d. Calcium channel blockers
e. Cephalosporins and related antibiotics
f. Fluoroquinolones, oral
g. Glucocorticoids, oral
h. Immunosuppressives, oral
i. Iron, oral
j. Leukotriene modifiers
k. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
l. Ophthalmic antibiotics
m. Ophthalmic antibiotic-steroid combinations
n. Ophthalmic for allergic conjunctivitis
o. Ophthalmic, anti-inflammatories
p. Ophthalmic, anti-inflammatories/immunomodulator
q. Ophthalmic, glaucoma agents
r. Otic antibiotics
s. Otic anti-infectives and anesthetics
t. Progestational agents
u. Sickle cell anemia treatments
v. Skeletal muscle relaxants
w. Steroids, topical high
x. Steroids, topical low
y. Steroids, topical medium
z. Steroids, topical very high
aa. Ulcerative colitis agents
»
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: » - a. Apadaz / Analgesics, Narcotics Short b. Inbrija / Antiparkinsons Agents c. Nivestym vial / Colony Stimulating Factors d. Tremfya Autoinjector, Skyrizi / Cytokine and Cell Adhesion Molecule (CAM) Antagonists e. Motegrity / Gastrointestinal (GI) Motility, Chronic f. Ingrezza Initiation Pack / Movement Disorders
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: »
a. Apadaz / Analgesics, Narcotics Short b. Inbrija / Antiparkinsons Agents
c. Nivestym vial / Colony Stimulating Factors
d. Tremfya Autoinjector, Skyrizi / Cytokine and Cell Adhesion Molecule (CAM) Antagonists
e. Motegrity / Gastrointestinal (GI) Motility, Chronic
f. Ingrezza Initiation Pack / Movement Disorders
»
6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Medication Adherence ii. Mental Health Disorders iii. Psychotropic Drug in Adults b. Report on recent retrospective DUR intervention outcomes: i. Benzodiazepine Anxiolytics and Controlled Sedative Hypnotics ii. Major Depressive Disorder Management c. Retrospective DUR proposals (vote required) i. Attention Deficit Hyperactivity Disorder (ADHD) Medication Management ii. Cough and Cold Medications iii. Influenza Prevention
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Medication Adherence
ii. Mental Health Disorders
iii. Psychotropic Drug in Adults
b. Report on recent retrospective DUR intervention outcomes:
i. Benzodiazepine Anxiolytics and Controlled Sedative Hypnotics
ii. Major Depressive Disorder Management
c. Retrospective DUR proposals (vote required)
i. Attention Deficit Hyperactivity Disorder (ADHD) Medication Management
ii. Cough and Cold Medications
iii. Influenza Prevention
»
7. Executive work session
7. Executive work session
»
8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
»
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) » - a. Cytokine and CAM antagonists - addition of Skyrizi (risankizumab-rzaa) b. GI Motility – Addition of Motegrity (prucalopride) c. Skeletal Muscle Relaxants - Update
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) »
a. Cytokine and CAM antagonists - addition of Skyrizi (risankizumab-rzaa) b. GI Motility – Addition of Motegrity (prucalopride)
c. Skeletal Muscle Relaxants - Update
»
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) » - a. Acetylcholinesterase Inhibitors b. Cyclooxygenase (COX)-2 Inhibitors c. Hepatitis C Direct Acting Antivirals d. Histamine H2-Receptor Antagonists e. Ketorolac f. Leukotriene Receptor Antagonists g. Mecasermin h. Memantine
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) »
a. Acetylcholinesterase Inhibitors b. Cyclooxygenase (COX)-2 Inhibitors
c. Hepatitis C Direct Acting Antivirals
d. Histamine H2-Receptor Antagonists
e. Ketorolac
f. Leukotriene Receptor Antagonists
g. Mecasermin
h. Memantine
»
Items 12 & 13 » - 12. Next meeting date: October 25, 2019 13. Adjourn
Items 12 & 13 »
12. Next meeting date: October 25, 2019 13. Adjourn
